RVL Pharmaceuticals
JoAnn Bonante possesses extensive experience in accounting and finance, currently serving as Sr. Director of Accounting at RVL Pharmaceuticals since July 2016, following a progression from Director of Accounting. Prior roles include Senior Manager of Accounting at The Medicines Company and Senior Manager of General Accounting at Mylan Specialty, LP. JoAnn has also held key positions at GeneraMedix, Inc., Baxter Healthcare, Warner Lambert, and AlliedSignal, showcasing a robust career that spans over three decades in various financial leadership roles. JoAnn earned a Bachelor's degree in Accounting from Seton Hall University between 1984 and 1988.
This person is not in any offices
RVL Pharmaceuticals
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.